Month: May 2020

VANCOUVER, British Columbia, May 04, 2020 (GLOBE NEWSWIRE) — CloudMD Software & Services Inc. (CSE: DOC, OTCQB: DOCRF, Frankfurt: 6PH) (the “Company” or “CloudMD”), a telemedicine company revolutionizing the delivery of healthcare to patients, is excited to announce that it has entered into a non-binding Letter of Intent (“LOI”) with Save-On-Foods and separately with Pure Integrative Pharmacy to pilot telemedicine kiosks in nine stores throughout British Columbia.For 6 weeks starting on May 26, 2020, CloudMD’s telemedicine software and services will be offered free of charge to Save-On-Foods and Pure Integrative Pharmacy clients. Telemedicine kiosks will be installed in existing private consult rooms in participating Save-On-Foods and Pure Integrative Pharmacy locations across BC. Patients will be able to see a doctor for prescription...

Constructive End of Phase 2 Meeting with FDA for Status Epilepticus Completed in March; Pivotal Phase 3 Clinical Trial Expected to Begin Next QuarterTopline Data on Track for Q3 2020 from Pivotal Phase 3 Marigold Study in CDKL5 Deficiency Disorder and Preparations Continue for Potential NDA FilingFirst Patients to be Screened this Quarter for Phase 2 Tuberous Sclerosis Complex Clinical TrialRADNOR, Pa., May 04, 2020 (GLOBE NEWSWIRE) — Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today provided an update on its clinical development activities and reported its financial results for the first quarter ended March 31, 2020.“We are proud to have made real progress across all of our clinical programs prior to and during the...

FuelCell Energy’s Power Platform Will Create a Cleaner Energy Profile for the City of San BernardinoRenewable Power Produced by the Fuel Cell will Contribute to California’s Decarbonization ObjectivesProprietary FuelCell Technology Drives Reduction in Particulates, NOx and SOx Following the Commercial Operation Date, FuelCell Energy Will Provide Low-Carbon Power Under a 20 Year Power Purchase Agreement To Supply San Bernardino Municipal Water DepartmentConstruction Financing Provided By Existing Orion Energy Partners Credit AgreementFuelCell Energy’s SureSource 1500 is the Only Fuel Cell Power Platform Certified by CARB for Operation on Biogas under the CARB 2013 Distributed Generation Emission Standards    DANBURY, Conn., May 04, 2020 (GLOBE NEWSWIRE) — FuelCell Energy, Inc. (Nasdaq: FCEL) — a global leader in fuel cell technology–with...

WALTHAM, Mass., May 04, 2020 (GLOBE NEWSWIRE) — Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the quarter ended March 31, 2020.“We are pleased to report that we are approaching the conclusion of the double-blind, 12-week phase of our pivotal Phase 3 trial with roluperidone and reiterate our previous guidance that we expect to report top line results in the second quarter,” said Dr. Remy Luthringer, Executive Chairman and Chief Executive Officer of Minerva. “Progress in this trial has been unaffected to date by the coronavirus pandemic and we are continually monitoring each trial site and our contract research organizations to ensure the safety...

DENVER, May 04, 2020 (GLOBE NEWSWIRE) — RLH Corporation (NYSE:RLH) announced today that it will release its first quarter 2020 results on Friday, May 8, 2020 before the open of the market.  Red Lion’s senior management team plans to host a webcast and conference call to review its financial results at 9:00 a.m. ET the same day.WEBCAST INFORMATIONThe live webcast can be accessed through the Investor Relations section of the Company’s website http://ir.redlion.com/events-and-presentations/events. The Company encourages use of the webcast due to potential extended wait times to access the conference call via dial-in.    CONFERENCE CALLFor those unable to access the webcast, the conference call will be accessible domestically or internationally, by dialing 877-407-8289 or 201-689-8341, respectively, and requesting the Red Lion Hotel...

NEW YORK, May 04, 2020 (GLOBE NEWSWIRE) — Virtu Financial, Inc. (NASDAQ: VIRT), a leading provider of financial services and products that leverages cutting edge technology to deliver liquidity to the global markets and provide execution services and data, analytics and connectivity products, today announced it has appointed Mr. Brett Fairclough and Mr. Joseph Molluso as Co-Presidents and Co-Chief Operating Officers of Virtu Financial.  Mr. Molluso will re-join Virtu after a brief period away from the company.Mr. Fairclough was promoted to Chief Operating Officer and Global Head of Business Development at Virtu in September of 2019, where he has worked since 2007. He led our Asia Pacific operations from 2014-2019 and was the Chief Compliance Officer of Virtu’s broker-dealer subsidiaries from 2012-2014.“Since assuming his expanded...

On track to meet the five clinical milestones expected in 2020 with no modifying guidance as a result of Covid-19Ongoing strong financial position with CHF 277.9 million in cash, ensuring the Company is fully financed through Q1 2024, excluding potential incoming milestonesAdded new potential CHF 60 million Phase 2 initiation milestone for the small molecule Morphomer™ Tau aggregation inhibitor program and received CHF 10 million milestone in Q1 2020 in Lilly partnershipAdvanced a lead anti-alpha-synuclein therapeutic antibody candidate into preclinical development based on new proof-of-concept data presented at AAT-AD/PDTMLAUSANNE, Switzerland, May 04, 2020 (GLOBE NEWSWIRE) — AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced...

BEDMINSTER, N.J., May 04, 2020 (GLOBE NEWSWIRE) — Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) — (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Monday, May 11, 2020 at 4:30 p.m. ET to discuss operational and financial results for the first quarter ended March 31, 2020.To participate in the call, please dial (877) 407-5976 (domestic) or (412) 902-0031 (international). The live webcast will be accessible on the Investors section of Matinas’ website, www.matinasbiopharma.com, and will be archived for 90 days.About Matinas BioPharmaMatinas BioPharma is a clinical-stage biopharmaceutical company focused on development of its lead product candidate, MAT9001, for the treatment of cardiovascular and metabolic...

TEL AVIV, Israel, May 04, 2020 (GLOBE NEWSWIRE) — VBL Therapeutics (Nasdaq: VBLT) is pleased to announce the publication of a new manuscript demonstrating the potential of MOSPD2 antibodies for Multiple Sclerosis (MS). VBL’s data offer a differentiated approach to potential treatment of central nervous system (CNS) inflammatory diseases using MOSPD2 antibodies that inhibit monocyte migration. Currently, there are no approved therapies for MS that target monocyte migration.VBL’s data show that knockout of the MOSPD2 gene in mice essentially protected the animals from developing CNS disease in the well-established EAE model for MS. Proprietary anti-MOSPD2 antibodies that block monocyte migration without affecting T-cells, were able to recapitulate this effect and profoundly reduced inflammation and tissue damage.“The...

Charlotte, N.C., May 04, 2020 (GLOBE NEWSWIRE) — Akoustis Technologies, Inc. (NASDAQ: AKTS) (“Akoustis” or the “Company”), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF filters for mobile and other wireless applications, announced today that management will attend the 5th Annual Oppenheimer Emerging Growth Conference which will be held virtually on May 12, 2020.Meetings will take place virtually given the ongoing call for social distancing due to the Covid-19 pandemic. Investors that would like to schedule a meeting with Akoustis management should contact their Oppenheimer sales representative or Akoustis’ investor relations at: ir@akoustis.com.Akoustis has added 12 filters to its product catalog including a 5.6 GHz filter, a 5.2 GHz WiFi filter, two small cell network infrastructure filters...